EpicBioCMYK300dpi.png
Epic Bio to Present at the Upcoming Annual European Society of Gene and Cell Therapy
19 oct. 2023 06h00 HE | Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
EpicBioCMYK300dpi.png
Epic Bio Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer
17 oct. 2023 06h00 HE | Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
22157.jpg
US Gene Editing Market Poised for Unprecedented Growth: Rice University's Breakthrough Technology Shines
10 oct. 2023 10h08 HE | Research and Markets
Dublin, Oct. 10, 2023 (GLOBE NEWSWIRE) -- In the midst of remarkable discoveries in gene editing, researchers at Rice University have unveiled a groundbreaking improvement to traditional CRISPR...
EpicBioCMYK300dpi.png
Epic Bio to Present at the Upcoming BMO Life Sciences Private Company Showcase
05 oct. 2023 09h00 HE | Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
EpicBioCMYK300dpi.png
Epic Bio to Present Preclinical Data at 28th International Annual Congress of the World Muscle Society
28 sept. 2023 09h00 HE | Epic Bio
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Dyadic Logo Current.jpg
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
26 sept. 2023 08h30 HE | Dyadic International, Inc.
JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA") today announced that they entered into a development and...
EpicBioCMYK300dpi.png
Epic Bio to Present at Upcoming BMO Biopharma Spotlight Series Event
19 sept. 2023 09h00 HE | Epic Bio
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
EpicBioCMYK300dpi.png
Epic Bio Reports Discovery of Exceptionally Durable Gene Activators and Creation of Machine Learning Algorithm to Design New Activators
14 sept. 2023 12h00 HE | Epic Bio
- Vast high-throughput screening study used to train unique machine learning algorithm to design synthetic activators - - Rational engineering produced activators that induce the most...
Caribou_logo.png
Caribou Biosciences to Participate in Upcoming Investor Conferences
29 août 2023 16h00 HE | Caribou Biosciences, Inc.
BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Global Gene Editing Market
Asia Pacific Emerges as Global Gene Editing Market Hotspot with High Growth Projections to 2028
28 août 2023 05h13 HE | Research and Markets
Dublin, Aug. 28, 2023 (GLOBE NEWSWIRE) -- The "Global Gene Editing Market by Product & Service (Reagents, Consumables, Systems, Software), Technology (CRISPR, TALEN, ZFN, Antisense), Application...